Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Antibody effector functions are crucial part of treating COVID-19 infections

Of the nine treatments and preventives for COVID-19 authorized for emergency use by the Food and Drug Administration, three are drugs made from so-called monoclonal antibodies.

17 Feb 2021

Scientists to develop highly sensitive antibody tests for infection caused by all coronaviruses

Scientists at the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health and SunYat-Sen University in China have set the stage for the development of highly sensitive antibody tests for infection with all known human coronaviruses, including new variants of SARS-CoV-2.

17 Feb 2021

Antibody testing is key to understand immune response to SARS-CoV-2

While PCR testing has been used widely for COVID-19 diagnosis, it only provides information on who is currently infected. Antibody testing can tell who has been previously exposed to SARS-CoV-2, the virus that causes COVID-19, a metric that is essential for tracking spread across a population.

17 Feb 2021

Detection of emerging SARS-CoV-2 variant in New York

Researchers at the California Institute of Technology in Pasadena have developed a software tool called "Variant Database" that has detected an emerging lineage of severe acute respiratory coronavirus 2 (SARS-CoV-2) isolates in New York.

16 Feb 2021

British and South African SARS-CoV-2 variants show some resistance to neutralizing antibodies

Researchers in France report impaired neutralization of two new SARS-CoV-2 variants by antibodies induced by vaccination or natural infection.

16 Feb 2021

Clonally expanded plasma cell lineages in SARS-CoV-2 produce specific neutralizing antibodies

A new preprint research paper posted to the bioRxiv server provides a greater understanding of the aspect of humoral immunity against the virus – the plasma cells that pour out a flood of specific antibodies targeting various epitopes on the pathogen.

16 Feb 2021

Mink-derived SARS-CoV-2 mutations reduce antibody effectiveness

A new preprint research paper posted to the bioRxiv* server shows that these mutations disrupt inhibition by neutralizing antibodies, both natural and therapeutic.

16 Feb 2021

Researchers create new cancer optotheranostics based on photosynthetic bacteria

Cancer is one of the most thought-provoking healthcare problems throughout the world. The development of therapeutic agents with highly selective anti-cancer activities is increasingly attractive due to the lack of tumor selectivity of conventional treatments.

16 Feb 2021

Elevated Activin A and FLRG levels correlate with worst outcomes in severe COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes a "cytokine storm" in hospitalized and ICU patients. Studies have shown that the blockade of cytokine signaling and steroid treatment helps achieve positive outcomes in patients.

15 Feb 2021

Nanoparticle COVID-19 vaccine stimulates robust and long lasting immunity in primates

In the study, published on the preprint server bioRxiv, the team evaluated the ability of AS03, CpG 1018 formulated in Alum, the TLR-7 agonist adsorbed to Alum (AS37), the squalene-in-water emulsion (O/W), and Alum to boost protective immunity against SARS-CoV-2.

15 Feb 2021

Research shows rapid global spread of Southern California COVID-19 strain

A new strain of the coronavirus in Southern California, first reported last month by Cedars-Sinai, is rapidly spreading across the country and around the world as travelers apparently carry the virus with them to a growing list of global destinations, according to new research published today in the peer-reviewed Journal of the American Medical Association.

15 Feb 2021

Study: Targeted therapy prolongs survival in patients with advanced bladder cancer

In a new study led by researchers at Yale Cancer Center, the drug enfortumab vedotin (EV) significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma or bladder cancer, who had previously received platinum-based treatment and a PD-1–PD-L1 inhibitor.

15 Feb 2021

Pitt scientists develop fast, efficient technique for discovering tiny antibody fragments

By capitalizing on a convergence of chemical, biological and artificial intelligence advances, University of Pittsburgh School of Medicine scientists have developed an unusually fast and efficient method for discovering tiny antibody fragments with big potential for development into therapeutics against deadly diseases.

15 Feb 2021

Researchers observe rapid increase of SARS-CoV-2 antibodies in plasma over pandemic's course

Researchers found that neutralizing antibodies against SARS-CoV-2 can increase over time. They observed that samples taken from convalescent plasma in September 2020 would likely have high enough values by July 2021 to protect immunodeficient patients who receive intravenous immunoglobulins as part of their treatment.

15 Feb 2021

SARS-CoV-2 South Africa and Brazil variants show resistance to therapeutic antibodies

Scientists from Germany have determined the efficacy of currently used therapeutics in treating newer variants of SARS-CoV-2, including the UK, South Africa, and Brazil variants. Their findings reveal that both B.1.351 and B.1.1.248 variants are able to escape humoral immune responses induced by therapeutic antibodies, vaccinations, or natural SARS-CoV-2 infection.

15 Feb 2021

Researchers develop protocols for rapid serological surveys of SARS-CoV-2 infection

A new study by researchers from Emory and Yale Universities in the USA discusses a design for quickly launching serological surveys to assess the prevalence of this infection in a given population.

15 Feb 2021

Immunosuppressive therapies may be linked to severe COVID-19 in those with multiple sclerosis

A new study examines the associations between immunosuppressive disease-modifying therapies (DMTs) used in MS with adverse outcomes in an international cohort of patients with MS COVID-19.

15 Feb 2021

Nanobodies protect against SARS-CoV-2 variants in animal model

Nanobodies are a potential therapeutic strategy for treating COVID-19. While many previous studies report nanobodies active against SARS-CoV-2 in vitro, none have been evaluated via animal models' intranasal administration.

15 Feb 2021

Naïve B cells can neutralize SARS-CoV-2 via RBD recognition

A new preprint research paper posted to the bioRxiv server demonstrates the potential of using the pre-existing protective responses to produce a broad-spectrum neutralizing response against not just SARS-CoV-2 but other future pathogens.

14 Feb 2021

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

Researchers from Cuba, China, and France have demonstrated the potential of coupling a viral antigen with the tetanus toxoid protein as a vaccination approach to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

14 Feb 2021

Antibody News and Research

Further Reading

Antibody effector functions are crucial part of treating COVID-19 infections

Scientists to develop highly sensitive antibody tests for infection caused by all coronaviruses

Antibody testing is key to understand immune response to SARS-CoV-2

Detection of emerging SARS-CoV-2 variant in New York

British and South African SARS-CoV-2 variants show some resistance to neutralizing antibodies

Clonally expanded plasma cell lineages in SARS-CoV-2 produce specific neutralizing antibodies

Mink-derived SARS-CoV-2 mutations reduce antibody effectiveness

Researchers create new cancer optotheranostics based on photosynthetic bacteria

Elevated Activin A and FLRG levels correlate with worst outcomes in severe COVID-19

Nanoparticle COVID-19 vaccine stimulates robust and long lasting immunity in primates

Research shows rapid global spread of Southern California COVID-19 strain

Study: Targeted therapy prolongs survival in patients with advanced bladder cancer

Pitt scientists develop fast, efficient technique for discovering tiny antibody fragments

Researchers observe rapid increase of SARS-CoV-2 antibodies in plasma over pandemic's course

SARS-CoV-2 South Africa and Brazil variants show resistance to therapeutic antibodies

Researchers develop protocols for rapid serological surveys of SARS-CoV-2 infection

Immunosuppressive therapies may be linked to severe COVID-19 in those with multiple sclerosis

Nanobodies protect against SARS-CoV-2 variants in animal model

Naïve B cells can neutralize SARS-CoV-2 via RBD recognition

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo